-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 26, 2021 //---According to a recent study published in the journal Nature, immunotherapy is not only significantly ineffective for liver cancer patients who had previously suffered from non-alcoholic steatohepatitis (NASH), but it actually seems Promote the growth of tumors.
Researchers have led a large international collaboration to study the effects of immunotherapy on fatal hepatocellular carcinoma (HCC) caused by NASH.
They conducted a meta-analysis of three randomized phase 3 clinical trials of immunotherapy in HCC and found that in non-viral HCC cases (such as NASH-related HCC), the effectiveness of treatment was significantly lower than that of virus-related HCC cases .
They conducted a meta-analysis of three randomized phase 3 clinical trials of immunotherapy in HCC and found that in non-viral HCC cases (such as NASH-related HCC), the effectiveness of treatment was significantly lower than that of virus-related HCC cases .
(Image source:style="text-align: justify;">In addition, this study found in animal models that the use of anti-PD1 inhibitors for immunotherapy actually leads to tumor growth, rather than helping the immune system kill cancer cells and shrink tumors.
In these models, the researchers determined that immune cells called CD8 + PD1 + are the driving factors for tumor cell growth.
These cells were found to function abnormally and could not be subjected to immune surveillance.
In these models, the researchers determined that immune cells called CD8 + PD1 + are the driving factors for tumor cell growth.
These cells were found to function abnormally and could not be subjected to immune surveillance.
"In addition to allowing clinicians to optimize treatment regimens based on potential liver diseases, the knowledge gained through this research will also provide a basis for the design of further combination treatments to overcome current limitations and improve patients with these potential liver diseases.
Survival rate,” said Dr.
Josep Llovet, professor of medicine at Icahn School of Medicine at Mount Sinai and co-corresponding author.
"These results also indicate the need for sophisticated treatment strategies to treat underlying liver disease-related tumors.
"
Survival rate,” said Dr.
Josep Llovet, professor of medicine at Icahn School of Medicine at Mount Sinai and co-corresponding author.
"These results also indicate the need for sophisticated treatment strategies to treat underlying liver disease-related tumors.
"
Non-alcoholic fatty liver disease (NAFLD) is an aura of NASH, which is estimated to affect 25% of the global population, and up to 20% of patients will develop NASH.
NASH is proven to be a new risk factor for HCC, so this study investigated the impact of immunotherapy on NASH-related HCC.
NASH is proven to be a new risk factor for HCC, so this study investigated the impact of immunotherapy on NASH-related HCC.
The meta-analysis of this study was conducted on three high-quality Phase 3 clinical trials, including more than 1,600 HCC patients receiving anti-PD1 immunotherapy.
(Bioon.
com)
(Bioon.
com)
Source of information: com/news/2021-03-liver-cancer-resistant-immunotherapy-patients.
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Original source: Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
(Image source: style="text-align: justify;">In addition, this study found in animal models that the use of anti-PD1 inhibitors for immunotherapy actually leads to tumor growth, rather than helping the immune system kill cancer cells and shrink tumors.
In these models, the researchers determined that immune cells called CD8 + PD1 + are the driving factors for tumor cell growth.
These cells were found to function abnormally and could not be subjected to immune surveillance.
In these models, the researchers determined that immune cells called CD8 + PD1 + are the driving factors for tumor cell growth.
These cells were found to function abnormally and could not be subjected to immune surveillance.
"In addition to allowing clinicians to optimize treatment regimens based on potential liver diseases, the knowledge gained through this research will also provide a basis for the design of further combination treatments to overcome current limitations and improve patients with these potential liver diseases.
Survival rate,” said Dr.
Josep Llovet, professor of medicine at Icahn School of Medicine at Mount Sinai and co-corresponding author.
"These results also indicate the need for sophisticated treatment strategies to treat underlying liver disease-related tumors.
"
Survival rate,” said Dr.
Josep Llovet, professor of medicine at Icahn School of Medicine at Mount Sinai and co-corresponding author.
"These results also indicate the need for sophisticated treatment strategies to treat underlying liver disease-related tumors.
"
Non-alcoholic fatty liver disease (NAFLD) is an aura of NASH, which is estimated to affect 25% of the global population, and up to 20% of patients will develop NASH.
NASH is proven to be a new risk factor for HCC, so this study investigated the impact of immunotherapy on NASH-related HCC.
NASH is proven to be a new risk factor for HCC, so this study investigated the impact of immunotherapy on NASH-related HCC.
The meta-analysis of this study was conducted on three high-quality Phase 3 clinical trials, including more than 1,600 HCC patients receiving anti-PD1 immunotherapy.
(Bioon.
com)
(Bioon.
com)
Source of information: com/news/2021-03-liver-cancer-resistant-immunotherapy-patients.
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Original source: Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
"In addition to allowing clinicians to optimize treatment regimens based on potential liver diseases, the knowledge gained through this research will also provide a basis for the design of further combination treatments to overcome current limitations and improve patients with these potential liver diseases.
Survival rate,” said Dr.
Josep Llovet, professor of medicine at Icahn School of Medicine at Mount Sinai and co-corresponding author.
"These results also indicate the need for sophisticated treatment strategies to treat underlying liver disease-related tumors.
"
Survival rate,” said Dr.
Josep Llovet, professor of medicine at Icahn School of Medicine at Mount Sinai and co-corresponding author.
"These results also indicate the need for sophisticated treatment strategies to treat underlying liver disease-related tumors.
"
Non-alcoholic fatty liver disease (NAFLD) is an aura of NASH, which is estimated to affect 25% of the global population, and up to 20% of patients will develop NASH.
NASH is proven to be a new risk factor for HCC, so this study investigated the impact of immunotherapy on NASH-related HCC.
NASH is proven to be a new risk factor for HCC, so this study investigated the impact of immunotherapy on NASH-related HCC.
The meta-analysis of this study was conducted on three high-quality Phase 3 clinical trials, including more than 1,600 HCC patients receiving anti-PD1 immunotherapy.
(Bioon.
com)
(Bioon.
com)
Source of information: com/news/2021-03-liver-cancer-resistant-immunotherapy-patients.
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Original source: Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
Non-alcoholic fatty liver disease (NAFLD) is an aura of NASH, which is estimated to affect 25% of the global population, and up to 20% of patients will develop NASH.
NASH is proven to be a new risk factor for HCC, so this study investigated the impact of immunotherapy on NASH-related HCC.
NASH is proven to be a new risk factor for HCC, so this study investigated the impact of immunotherapy on NASH-related HCC.
The meta-analysis of this study was conducted on three high-quality Phase 3 clinical trials, including more than 1,600 HCC patients receiving anti-PD1 immunotherapy.
(Bioon.
com)
(Bioon.
com)
Source of information: com/news/2021-03-liver-cancer-resistant-immunotherapy-patients.
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Original source: Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
The meta-analysis of this study was conducted on three high-quality Phase 3 clinical trials, including more than 1,600 HCC patients receiving anti-PD1 immunotherapy.
(Bioon.
com)
(Bioon.
com)
Source of information: com/news/2021-03-liver-cancer-resistant-immunotherapy-patients.
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Original source: Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
Source of information: com/news/2021-03-liver-cancer-resistant-immunotherapy-patients.
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Source of information: com/news/2021-03-liver-cancer-resistant-immunotherapy-patients. html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Original source: Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
html">Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Original source: Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
Original source: Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
Original source: NASH limits anti-tumour surveillance in immunotherapy-treated HCC Nature NASH limits anti-tumour surveillance in immunotherapy-treated HCC , Nature (2021).
DOI: 10.
1038/s41586-021-03362-0, dx.
doi.
org/ 10.
1038/s41586-021-03362-0
